Neurocrine Biosciences, Inc. (NBIX) Q3 2021 Earnings Results

Neurocrine Biosciences Beats on EPS, Stock Up 0.77%

Neurocrine Biosciences reported a strong EPS performance, exceeding expectations by nearly 25%. The stock reacted positively, rising by 0.77%. However, the lack of revenue data and guidance may leave investors cautious about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.64	N/A	+24.76%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed satisfaction with the earnings performance. They highlighted their focus on future opportunities while remaining cautious.

The company is pleased with the EPS results despite not providing revenue figures.

Management emphasized their commitment to long-term growth and innovation.

Neurocrine Biosciences Beats on EPS, Stock Up 0.77%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Beats on EPS, Stock Up 0.77%

Key numbers

Management commentary